Amgen files update to Tavneos label as FDA escalates push to withdraw news2026-05-01T13:02:29+00:00May 1st, 2026|Endpoints News|
Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debutnews2026-05-01T11:34:58+00:00May 1st, 2026|Endpoints News|
J&J axes pair of CAR-T therapies for lymphoma, citing evolving marketnews2026-05-01T11:07:45+00:00May 1st, 2026|Endpoints News|
Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exitnews2026-05-01T11:00:31+00:00May 1st, 2026|Endpoints News|
FDA’s oncology advisors vote against ‘new paradigm’ in AstraZeneca trialnews2026-04-30T18:56:01+00:00April 30th, 2026|Endpoints News|
Krazati fails confirmatory trial in colorectal cancer, putting approval at risknews2026-04-30T18:37:50+00:00April 30th, 2026|Endpoints News|
House panel calls to ban China trial data from FDA drug trial applicationsnews2026-04-30T18:28:13+00:00April 30th, 2026|Endpoints News|
Court dismisses part of Lilly lawsuit against Empower, some claims can proceednews2026-04-30T18:16:20+00:00April 30th, 2026|Endpoints News|
Supreme Court questions how far generics makers can go with ‘skinny label’ drugsnews2026-04-30T18:10:37+00:00April 30th, 2026|Endpoints News|
Avalyn’s upsized IPO; Alector ends another study in GSK partnershipnews2026-04-30T15:33:40+00:00April 30th, 2026|Endpoints News|
